Personalized Medicine, Genomics and Enhancement: Monuments to Neoliberalism
American Journal of Clinical and Experimental Medicine
Volume 5, Issue 3, May 2017, Pages: 75-92
Received: Mar. 24, 2017; Accepted: Apr. 6, 2017; Published: Apr. 30, 2017
Views 2204      Downloads 108
Authors
Charles Joseph Kowalski, Health and Behavioral Sciences IRB, Office of Research, University of Michigan, Ann Arbor, USA
Adam Joel Mrdjenovich, Health and Behavioral Sciences IRB, Office of Research, University of Michigan, Ann Arbor, USA
Article Tools
Follow on us
Abstract
This essay explores the meanings, possibilities, limitations, and some of the relationships between three currently much discussed – and debated – topics: personalized medicine, genomics, and enhancement. We believe, and gather in one place some of the literature supporting the view that all three are largely the product of the current dominant ideology of neoliberalism with its emphasis on individual freedom of choice, unwavering trust in the “wisdom of the market,” the commodification of everything, including information and promise, and the associated scientific viewpoints it employs, reductionism and biological (especially genetic) determinism. We recognize that the success (or failure) of approaches to problems based on reductionism and/or genetic influences depends upon the problem(s) considered and the uses to which the accumulating insight will be employed. We believe that we can often do better than focusing on profit motives when determining which problems to study and which outcomes are most useful.
Keywords
Biological Determinism, Reductionism, -Omics, Medicalization, Horses for Courses
To cite this article
Charles Joseph Kowalski, Adam Joel Mrdjenovich, Personalized Medicine, Genomics and Enhancement: Monuments to Neoliberalism, American Journal of Clinical and Experimental Medicine. Vol. 5, No. 3, 2017, pp. 75-92. doi: 10.11648/j.ajcem.20170503.14
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Dickenson D (2013) ME Medicine vs. WE Medicine: Reclaiming biotechnology for the common good. New York: Columbia University Press.
[2]
Harvey D (2005) A Brief History of Neoliberalism. New York: Oxford University Press.
[3]
Brown W (2015) Undoing the Demos: Neoliberalism’s stealth revolution. New York: Zone Books.
[4]
Mirowski P (2014) Never Let A Serious Crisis Go To Waste: How neoliberalism survived the financial meltdown. New York: Verso.
[5]
Michaels D (2008) Doubt is their Product: How industry’s assault on science threatens your health. Oxford University Press.
[6]
Resnik DB (2007) The Price of Truth: How money affects the norms of science. Oxford University Press.
[7]
Ginsburg GS and Willard HF (2009) Genomic and personalized medicine: foundations and applications. Translational Research 154(6): 277-287.
[8]
Giroux HA (2014) Neoliberalism’s War on Higher Education. Chicago IL: Haymarket Books.
[9]
Olssen M and Peters M (2005) Neoliberalism, higher education and the knowledge economy: from the free market to knowledge capitalism. Journal of Education Policy 20(3): 313-345.
[10]
Fisher JA (2009) Medical Research for Hire: The political economy of pharmaceutical clinical trials. New Brunswick NJ: Rutgers University Press.
[11]
Esposito L and Perez FM (2014) Neoliberalism and the commodification of mental health. Humanity & Society 38(4): 414-442.
[12]
Rissmiller DJ and Rissmiller JH (2006) Evolution of the antipsychiatry movement into mental health consumerism. Psychiatric Services 57(6): 863-866.
[13]
Everett B (2000) A fragile revolution: Consumers and psychiatric survivors confront the power of the mental health system. Waterloo, Ontario: Wilfrid Laurier University Press.
[14]
Lewontin R, Rose S and Kamin LJ (1984) Not in our Genes: Biology, Ideology, and Human Nature. New York: Pantheon.
[15]
Nelkin D and Lindee MS (2004) The DNA Mystique. Ann Arbor MI: University of Michigan Press.
[16]
Midgley M (2010) The Solitary Self: Darwin and the selfish gene. New York: Routledge.
[17]
Ridley M (1999) Genome: The autobiography of a species in 23 chapters. New York: Harper Perennial.
[18]
Rajan KS (2006) Biocapital: The constitution of postgenomic life. Durham NC: Duke University Press.
[19]
Rose N (2007) The Politics of Life Itself: Biomedicine, power, and subjectivity in the twenty-first century. Princeton NJ: Princeton University Press.
[20]
Chadwick R (2014) The ethics of personalized medicine: A philosopher’s perspective. Personalized Medicine 11(1): 5-6.
[21]
Fleck LM (2010) Personalized medicine’s ragged edge. Hastings Center Report 40(5): 16-18.
[22]
Personalized Medicine Coalition (2014) The Case for Personalized Medicine. Fourth edition. Available at: www.personalizedmedicinecoalition.org (Accessed January 30, 2017).
[23]
Hamburg MA and Collins FS (2010) The path to personalized medicine. New England Journal of Medicine 363(4): 301-304.
[24]
Kowalski CJ and Mrdjenovich AJ (2013) Patient preference trials: Why and when they will sometimes be preferred. Perspectives in Biology and Medicine 56(1): 18-35.
[25]
Gamma A (2014) The role of genetic information in personalized medicine. Perspectives in Biology and Medicine 56(4): 485-512.
[26]
Gilbert W (1992) A vision of the grail. In: D. J. Kevles, and L. Hood, eds. The Code of Codes: Scientific and social issues in the human genome project. Cambridge MA: Harvard University Press, pp. 83-97.
[27]
Carey N (2012) The Epigenetic Revolution. How modern biology is rewriting our understanding of genetics, disease, and inheritance. New Kork: Columbia University Press.
[28]
Keller EF (1995) Refiguring Life: Metaphors of twentieth-century biology. New York: Columbia University Press.
[29]
Panofsky A (2015) From behavior genetics to postgenomics. In: Richardson SS and Stevens H (eds) Postgenomics: Perspectives on Biology after the Genome. Durham NC: Duke University Press: pp. 150-73.
[30]
Keller EF (2015) The postgenomic genome. In: Richardson SS and Stevens H (eds) Postgenomics: Perspectives on Biology after the Genome. Durham NC: Duke University Press: pp. 9-31.
[31]
Stevens H and Richardson SS (2015) Beyond the genome. In: Richardson SS and Stevens H (eds) Postgenomics: Perspectives on Biology after the Genome. Durham NC: Duke University Press: pp. 1-8.
[32]
Keller EF (2010) The Mirage of a Space between Nature and Nurture. Durham NC: Duke University Press.
[33]
Graeber D (2015) The Utopia of Rules: On technology, stupidity. Brooklyn NY: Melville House.
[34]
Kevles DJ and Hood L (eds) (1992) The Code of Codes: Scientific and social issues in the human genome project. Cambridge MA: Harvard University Press.
[35]
Lewontin R (1991) Biology as Ideology. New York: Harper Collins.
[36]
Tauber AJ and Sarkar S (1992) The Human Genome Project: Has blind reductionism gone too far? Perspectives in Biology and Medicine 35(2): 220-235.
[37]
Strohman RC (1993) Ancient genomes, wise bodies, unhealthy people: Limits of a genetic paradigm in biology and medicine. Perspectives in Biology and Medicine 37(1): 112-145.
[38]
Hood L (1992) Biology and medicine in the twenty-first century. In: Kevles DJ and Hood L (eds) The Code of Codes: Scientific and social issues in the human genome project. Cambridge MA: Harvard University Press: pp. 136-163.
[39]
Fortun M (2005) For an ethics of promising, or: a few kind words for James Watson. New Genetics and Society 24(2): 157-173.
[40]
Fortun M (2008) Promising Genomics: Iceland and deCODE Genetics in a world of speculation. Berkeley CA: University of California Press.
[41]
Rose N (2013) Personalized medicine: Promises, problems and perils of a new paradigm for healthcare. Procedia – Social and Behavioral Sciences 77: 341-352.
[42]
Frazer KA, Ballinger DG, Cox DR et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449(7164): 851-861.
[43]
Rose N (2008) Race, risk and medicine in the age of ‘Your Own Personal Genome.’ BioSocieties 3(4): 423-439.
[44]
Visscher PM, Brown MA, McCarthy MI et al. (2012) Five years of GWAS discovery. American Journal of Human Genetics 90(1): 7-24.
[45]
Stranger BE, Stahl EA and Raj T (2011) Progress and promise of genome-wide association studies for human complex trait genetics. Genetics 187(2): 367-383.
[46]
Lango AH, Estrada K, Lettre G et al. (2010) Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467(7317): 832-838.
[47]
Steele EJ (2014) Reflections on ancestral haplotypes: Medical genomics, evolution, and human individuality. Perspectives in Biology and Medicine 57(2): 179-197.
[48]
Patel CJ, Bhattacharaya J and Butte AL (2010) An environment-wide association study (EWAS) on Type 2 diabetes mellitus. PLoS One 5: 1-10. e10746.
[49]
Khoury MJ and Wacholder S (2008) From Genome-Wide association studies to Gene-Environment-Wide interaction studies -- Challenges and opportunities. American Journal of Epidemiology 169(2): 227-230.
[50]
Gigerenzer G (1991) From tools to theories: A heuristic of discovery on cognitive psychology. Psychological Review 98(2): 254-67.
[51]
Lewontin R (2001) It Ain’t Necessarily So: The dream of the human genome and other illusions. Second edition. New York: The New York Review of Books.
[52]
Pettigrew M and Roberts H (2003) Evidence, hierarchies, and typologies: horses for courses. Journal of Epidemiology and Community Health 57(7): 527-529.
[53]
Kowalski CJ and Mrdjenovich AJ (2014) Comparative effectiveness research. Perspectives in Biology and Medicine 57(2): 224-248.
[54]
Arrow KJ (1963) Uncertainty and the welfare economics of medical care. The American Economic Review 53(5): 941-973.
[55]
Nerlich B and Hellsten L (2009) Beyond the human genome: microbes, metaphors and what it means to be human in an interconnected post-genomic world. New Genetics and Society 28(1): 19-36.
[56]
Schneider CW and Winslow R (2014) The human microbiome, ecological ontology, and the challenges of community. Perspectives in Biology and Medicine 57(2): 208-23.
[57]
Blaser M, Bork P, Fraser C, Knight R and Wang J (2013) The microbiome explored: recent insights and future challenges. Nature Reviews Microbiology 11: 213-17.
[58]
Shostak S and Moinester M (2015) The missing piece of the puzzle? Measuring the environment in the postgenomic moment. In: Richardson SS and Stevens H (eds) Postgenomics: Perspectives on Biology after the Genome. Durham NC: Duke University Press: pp 192-209.
[59]
Parrington J (2015) The Deeper Genome: Why there is more to the human genome than meets the eye. Oxford University Press.
[60]
Graur DY, Zheng Y, Price N et al. (2013) On the immortality of television sets: ’function’ in the human genome according to the evolution-free gospel of ENCODE. Genome Biology and Evolution 5(3): 578-590.
[61]
Green ED, Watson JD and Collins FS (2015) Human Genome Project: Twenty-five years of big biology. Nature Comment 30 September 2015.
[62]
Hood L and Rowen L (2013) The Human Genome Project: big science transforms biology and medicine. Genome Medicine 5(9): 79.
[63]
Tripp S and Greuber M (2011) Economic Output of the Human Genome Project. Columbus: Battelle Memorial Institute.
[64]
Miklos GL (2005) The Human Cancer Genome Project – one more misstep in the war on cancer. Nature Biotechnology 23: 535-537.
[65]
Leaf C (2004) Why we’re losing the war on cancer (and how to win it). Fortune 149(6): 76-97.
[66]
Brown PO and Botstein D (1999) Exploring the new world of the genome with DNA microarrays. Nature Genetics Supplement 21: 33-37.
[67]
Buchanan A (2011a) Beyond humanity? Oxford: Oxford University Press.
[68]
Healy D (2002) The Creation of Psychopharmacology. Cambridge MA: Harvard University Press.
[69]
Gronfein W (1985) Psychotropic drugs and the origins of deinstitutionalization. Social Problems 32(5): 437-454.
[70]
Moncrieff J (2006) Psychiatric drug promotion and the politics of neoliberalism. British Journal of Psychiatry 188(4): 301-302.
[71]
Hamilton C (2003) Growth Fetish. Crow’s Nest, NSW, Australia: Allen & Unwin.
[72]
Temkin LS (2013) What’s wrong with enhancement? Journal of Medical Ethics 39(12): 729-731.
[73]
Midgley M (2004) The Myths We Live By. New York: Routledge.
[74]
Quackenbush J (2011) The Human Genome. Watertown MA: Charlesbridge Publishing.
[75]
McGowan ML and Fishman JR (2008) Using lessons learned from BRCA testing and marketing: What lies ahead for whole genome scanning services. American Journal of Bioethics 8(6): 18-20.
[76]
Bazell R (1998) Her-2: The making of Herceptin, a revolutionary treatment for breast cancer. New York: Random House.
[77]
Gillick MR (2014) Targeted chemotherapy, the medical ecosystem, and the future of American health care. Perspectives in Biology and Medicine 57(2): 268-284.
[78]
Callahan D and Wasunna AA (2006) Medicine and the Market: Equity v. choice. Baltimore MD: Johns Hopkins University Press.
[79]
Conrad P (2006) Up, down, and sideways. Society 43(6): 19-20.
[80]
Armitage P (1984) Controversies and achievements in clinical trials. Controlled Clinical Trials 5(1): 67-72.
[81]
Rothwell PM (ed) (2007) Treating Individuals: From randomized trials to personalized medicine. Edinburgh: Elsevier.
[82]
Hubbard R and Wald E (1999) Exploding the Gene Myth: How genetic information is produced and manipulated by scientists, physicians, employers, insurance companies, educators, and law enforcers. Boston MA: Beacon Press.
[83]
Seligman MEP and Csikszentmihalyi M (2000) Positive psychology: An introduction. American Psychologist 55(1): 5-14.
[84]
Juengst ET (2004) Concepts of disease after the human genome project. In: Caplan AL, McCartney JJ and Sisti DA (eds) Health, Disease and Illness. Washington DC: Georgetown University Press: pp. 243-62.
[85]
Mahar M (2006) Money-Driven Medicine: The real reason health care costs so much. New York: HarperCollins.
[86]
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders (5th ed). Washington DC: American Psychiatric Association.
[87]
National Institute of Mental Health (2013) Statistics. Available at: http://www.nimh.nih. gov/health/publications/the-numbers-count-mental-disorders-in-america/index.shtml (Accessed January 30, 2017).
[88]
Seligman MEP (1994) What You Can Change & What You Can't. New York: Knopf.
[89]
Susser ES, Schwartz S, Morabia A et al. (2006) Psychiatric epidemiology: Searching for the causes of mental disorders. New York: Oxford University Press.
[90]
Aanstoos C, Serlin I and Greening T (2000) A history of Division 32. In D. Dewsbury (ed) Unification through division: Histories of the Divisions of the American Psychological Association. Washington DC: American Psychological Association.
[91]
McLeroy KR, Bibeau D, Steckler A et al. (1988) An ecological perspective on health promotion programs. Health Education Quarterly 15(4): 351-377.
[92]
Mrdjenovich AJ and Moore BA (2004) The professional identity of counseling psychologists in health care settings. Counselling Psychology Quarterly 17(1): 69-79.
[93]
Sallis JF and Owen N (2002) Ecological models of health behavior. In: Glanz K, Rimer BK and Lewis FM (eds) Health Behavior and Health Education: Theory, research, and practice. San Francisco CA: Jossey Bass.
[94]
American Psychological Association Presidential Task Force (2006) Evidence-based practice in psychology. American Psychologist 61(4): 271-285.
[95]
Kupfer DJ, Kuhl EA and Regier DA (2013) DSM-5—The future arrived. Journal of the American Medical Association 309(16): 1691-1692.
[96]
Anthony W, Rogers ES and Farkas M (2003) Research on evidence-based practices: Future directions in an era of recovery. Community Mental Health Journal 39(2): 101-114.
[97]
Deegan PE (1997) Recovery and empowerment for people with psychiatric disabilities. Social Work in Health Care 25(3): 11-24.
[98]
Frese FJ, Stanley J, Kress K et al. (2001) Integrating evidence-based practices and the recovery model. Psychiatric Services 52(11): 1462-1468.
[99]
Ralph RO and Corrigan PW (2005) Recovery in mental illness: Broadening our understanding of wellness. Boston MA: Boston University Center for Psychiatric Rehabilitation.
[100]
Callahan D (2009) Medicine and the market. In: DG Arnold (ed) Ethics and the Business of Biomedicine, Cambridge University Press.
[101]
Koch T (2012) Thieves of Virtue: When Bioethics stole Medicine. Cambridge MA: MIT Press.
[102]
Callahan D (1987) Setting Limits: Medical Goals in an Aging Society. New York: Simon and Schuster.
[103]
Callahan D (1990) What Kind of Life? The Limits of Medical Progress. Washington DC: Georgetown University Press.
[104]
Kowalski CJ, Hutchinson RJ and Mrdjenovich AJ (2017) The ethics of clinical care and the ethics of clinical research: Yin and yang. Journal of Medicine and Philosophy 42(1): 7-32.
[105]
Mayes CB, Blakely I, Kerridge P et al. (2016) On the fragility of medical virtue in a neoliberal context: the case of commercial conflicts of interest in reproductive medicine. Theoretical Medicine and Bioethics 37(1): 97-111.
[106]
Medawar PB and Medawar JS (1983) Aristotle to Zoos: A philosophical dictionary of biology. Cambridge MA: Harvard University Press.
[107]
Lewontin R and Levins R (2007) Biology Under the Influence: Dialectical essays on ecology, agriculture, and health. New York: Monthly Review Press.
[108]
Esparza J and Yamada T (2007) The discovery value of “Big Science.” Journal of Experimental Medicine 204(4): 701-704.
[109]
Weinberg AM (1967) Reflections on Big Science. Cambridge MA: MIT Press.
[110]
Sabin AB (1967) Collaboration for accelerating progress in medical research. Science 156(3782): 1568-1571.
[111]
Kell DB and Oliver SG (2003) Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. BioEssays 26(1): 99-105.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186